Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts

Movement Disorders

Volumn 29, Issue 14, 2014, Pages 1767-1773

  Kraemmer, Julia ^a   Kovacs, Gabor G ^b   Perju Dumbrava, Laura ^a   Pirker, Susanne ^a   Traub Weidinger, Tatiana ^a   Pirker, Walter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cell count; Dopamine transporter; Iodine 123 2 carbomethoxy 3 (4 iodophenyl)tropane ( 123I CIT); Single photon emission computed tomography; Substantia nigra

Indexed keywords

AMANTADINE; DOPAMINE TRANSPORTER; IODINE 123 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)TROPANE; LEVODOPA; MIANSERIN; NEUROMELANIN; PARAFFIN; QUETIAPINE; RADIOPHARMACEUTICAL AGENT; TAR DNA BINDING PROTEIN; TAU PROTEIN; TRAZODONE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; DOPAMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN CELL; CAUDATE NUCLEUS; CAUSE OF DEATH; CELL COUNT; CELL DENSITY; CELL LOSS; CORRELATION ANALYSIS; CORTICOBASAL DEGENERATION; CREUTZFELDT JAKOB DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; DOPAMINERGIC NERVE CELL; FEMALE; FUNCTIONAL NEUROIMAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; LEFT HEMISPHERE; LOW DRUG DOSE; MALE; MIDDLE AGED; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN BINDING; PUTAMEN; RETROSPECTIVE STUDY; RIGHT HEMISPHERE; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; TIME OF DEATH; CORPUS STRIATUM; METABOLISM; NEOSTRIATUM; PATHOLOGY; PROCEDURES;

AGED; AUTOPSY; CELL COUNT; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOSTRIATUM; PARKINSON DISEASE; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84918841209     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25975     Document Type: Article

References (24)

1. Seibyl J, Marek KL, Quinlan D, et al. Decreased single photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
2. Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
3. Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2013;2013:1288-1295.
4. de la Fuente-Fernández R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology 2012;78:696-701.
5. 3I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models in Parkinson's disease. NeuroImage 2007;38:5-12.
6. Andringa G, Drukarch B, Bol JGJM, et al. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease. NeuroImage 2005;26:1150-1158.
7. Ashkan K, Wallace BA, Mitrofanis J, et al. SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson's disease. Parkinsonism Relat Disord 2007;13:266-275.
8. 3I]β-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions inuced by 6-OHDA in rats. EJNMMI Research 2013;3:47.
9. 3I]altropane binding in the rat model of Parkinson's. Nucl Med Biol 2011;38:741-749.
10. Karimi M, Tian L, Brown CA, et al. Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol 2013;73:390-396.
11. Pate B, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993;34:331-338.
12. Yee R, Irwin I, Milonas C, Stout DB, et al. Novel observations with FDOPA-PET imaging after early nogrostriatal damage. Mov Disord 2001;5:838-848.
13. Colloby S, McParland S, O'Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. Brain 2012;135:2798-2808.
14. Snow B, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
15. Kovacs G, Budka H. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clin Neuropathol 2010;29:271-288.
16. Ma S, Röyttä M, Rinne JO, Collan Y, Rinne UK. Single section and disector counts in evaluating neuronal loss from the substantia nigra in patients with Parkinson's disease. Neuropathol Appl Neurobiol 1995;21:1420-1426.
17. Parkkinen L, O'Sullivan SS, Kuoppamäki M, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 2011;77:1420-1426.
18. Pirker W, Asenbaum S, Bencsits G, et al. [123I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration. Mov Disord 2000;15:1158-1167.
19. Pirker W, Asenbaum S, Hauk M, et al. Imaging serotonin and dopamine transporters with iodine-123-β-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000;41:36-44.
20. Pirker W, Djamshidian S, Asenbaum S, et al. The progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal β-CIT SPECT study. Mov Disord 2002;17:45-53.
21. Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008;35:424-438.
22. Fearnley J, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
23. Kordower J, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136:2419-2431.
24. Morrish P, Rakshi JS, Bailey DL, Sawle GV. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa-PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.